Matthew Barcus
Stock Analyst at Chardan Capital
(2.36)
# 2,553
Out of 4,910 analysts
21
Total ratings
25%
Success rate
20.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $1.72 | +483.09% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $15.21 | +77.51% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.69 | +914.35% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $18.44 | +73.54% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.63 | +8,265.02% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.38 | +166.27% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $11.18 | -28.44% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.72
Upside: +483.09%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $15.21
Upside: +77.51%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.69
Upside: +914.35%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $18.44
Upside: +73.54%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.63
Upside: +8,265.02%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.38
Upside: +166.27%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $11.18
Upside: -28.44%